These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Expression and clinical significance of miR-193a-3p in invasive pituitary adenomas.
    Author: Su WJ, Wang JS, Ye MD, Chen WL, Liao CX.
    Journal: Eur Rev Med Pharmacol Sci; 2020 Jul; 24(14):7673-7680. PubMed ID: 32744693.
    Abstract:
    OBJECTIVE: Our study aimed to investigate miR-193a-3p expression and its clinical significance in pituitary adenomas (PAs). Moreover, the correlation between miR-193a-3p expression and the invasiveness of PAs was explored. PATIENTS AND METHODS: In this study, the relative expression levels of miR-193a-3p were detected via quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). The correlations between miR-193a-3p and tumor size, clinical features, and prolactinomas postoperative prolactin (PRL) levels early remission were further analyzed. RESULTS: Compared with non-invasive PAs, there was a lower miR-193a-3p expression in invasive PAs. MiR-193a-3p expression had reverse relevance to tumor size. A higher risk of postoperative residual and recurrence was found in patients with downregulated miR-193a-3p. Prolactinomas patients with postoperative PRL levels early remission were at lower risk to relapse and patients with high-expression miR-193a-3p had a higher early remission rate, suggesting that miR-193a-3p was a significant prognostic factor for prolactinomas. CONCLUSIONS: MiR-193a-3p could have potential therapeutic value for invasive pituitary adenomas.
    [Abstract] [Full Text] [Related] [New Search]